Longitudinal Assessment of Children with Mild CF Using Hyperpolarised Gas Lung MRI and LCI by Smith, L. et al.
This is a repository copy of Longitudinal Assessment of Children with Mild CF Using 
Hyperpolarised Gas Lung MRI and LCI.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/119058/
Version: Accepted Version
Article:
Smith, L. orcid.org/0000-0002-5769-423X, Marshall, H., Aldag, I. et al. (7 more authors) 
(2017) Longitudinal Assessment of Children with Mild CF Using Hyperpolarised Gas Lung 
MRI and LCI. American Journal of Respiratory and Critical Care Medicine. ISSN 
1073-449X 
https://doi.org/10.1164/rccm.201705-0894LE
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
 1 
Longitudinal assessment of children with mild CF using hyperpolarised gas 
lung MRI and LCI 
 
Authors:  Laurie Smith1,2, Helen Marshall1, Ina Aldag2, Felix Horn1, Guilhem 
Collier1, David Hughes2, Noreen West2, Alex Horsley3, Chris J Taylor2, Jim Wild1 
1POLARIS, University of Sheffield, Sheffield, UK 
2ǯ	ǡǡ 
3Respiratory Research Group, University of Manchester, Manchester, UK  
 
Corresponding Author: Jim Wild. j.m.wild@sheffield.ac.uk. (+44) 
(0)114  2159141. Academic Radiology, Department of Infection, Immunity & 
Cardiovascular Disease, University of Sheffield, Sheffield. 
 
Funding: This work was supported by grants from the: NIHR (NIHR-RP-R3-12-
027), MRC (MR/M008894/1) and Cystic Fibrosis Trust. LS, AH and JW were 
supported by the National Institute for Health Research (NIHR), LS was 
supported by an HEE/NIHR clinical doctoral research fellowship, AH was 
supported by an NIHR Clinician Scientist award and JW was supported by an 
NIHR Professorship award. The views expressed in this publication are those of 
the author(s) and not necessarily those of the NHS, the National Institute for 
Health Research or the Department of Health. 
 
Author Contributions: Concept and design Ȃ JW, CJT, AH. Analysis and 
interpretation Ȃ LS, HM, AH, GC, JW. Manuscript writing Ȃ LS, HM, AH, JW. 
Manuscript review Ȃ all authors. Pulmonary function testing Ȃ LS. MRI technical 
work Ȃ HM, FH, GC, JW. Patient recruitment/consent/support Ȃ IA, NW, CJT. JW 
underwrites the work. 
  
 2 
Introduction 
Improving life expectancy in patients with cystic fibrosis (CF) alongside annual 
rates of decline in FEV1 as low as 1-2% predicted per year (1), poses challenges 
for the use of spirometry as a measurement of longitudinal change. Spirometry is 
also insensitive to early changes in the CF lung, and lung clearance index (LCI) 
derived from multiple breath washout (MBW) has emerged as a promising 
alternative in patients with well-preserved spirometry, including children (2). 
 
Recently the potential of LCI in the longitudinal assessment of CF lung disease 
has been highlighted (3), though there are still questions with regards to the 
mechanisms behind the mixed LCI response seen in intervention studies (4-6). 
As a global metric however, LCI offers little information as to the location of any 
abnormality and the associated pathophysiology.  
 
Hyperpolarised gas ventilation magnetic resonance imaging (ventilation MRI) is 
a sensitive imaging technique that reveals the distribution of ventilation within 
the lung in exquisite detail, allowing regional ventilation heterogeneity to be 
assessed. Ventilation MRI has been shown to be highly sensitive to early lung 
function abnormalities in CF and other obstructive airways diseases before 
changes are manifested in spirometry (7-9).  
 
We have previously reported cross-sectional data on a cohort of 19 children with 
mild CF lung disease where ventilation MRI demonstrated lung defects when 
abnormality was often not detectable on either CT or LCI (8). The aim of the 
present study was to re-assess these children at a second time point 1-2 years 
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following the baseline visit and describe any observed longitudinal changes in 
lung function or ventilation MRI. Some of the results of these studies have been 
previously reported in the form of abstracts (10-12). 
 
 
Methods 
14 children with CF from the cohort previously reported (8) were re-assessed at 
a second time point between 1.3-2.0 years after baseline using helium-3 (3He) 
ventilation MRI, MBW, spirometry and body plethysmography using the same 
methods as previously described (8). Patients were clinically stable for at least 4 
weeks prior to both visits (free from exacerbation and needing no new 
treatments) and were on stable chronic medical regimens according to national 
guidelines. From the ventilation images two indices were calculated; (i) the 
ventilation defect percentage (VDP), which quantifies the fraction of the lung 
volume that is not ventilated, and (ii) the mean co-efficient of variance of 
ventilated image signal intensity (CVmean), a metric of ventilation heterogeneity. 
    ȋȟȌ     two was calculated for all 
metrics. Wilcoxon matched-pairs signed rank test and Spearman correlations 
were performed due to the small sample size.  
  
 
Results 
Patient demographics, lung function and MRI metrics at baseline and visit two 
are presented in Table 1. At baseline all children with CF had visible ventilation 
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defects, and VDP and CVmean were greater in CF patients than healthy controls (as 
reported previously (8)). From baseline to visit two there were significant group 
increases in VDP, CVmean and LCI, but not in spirometric indices (Table 1).  
 
Longitudinal changes in ventilation MRI 
VDP increased over time in 13/14 children, whilst 10/14 children showed 
increased CVmean at visit two compared to baseline. There was no single pattern 
of disease progression: in some patients, multiple small ventilation defects 
became apparent that were not visible at baseline (Figure 1, subjects A and B). 
Other patients had a visible progression in regions of ventilation abnormalities 
that were already present at baseline but had minimal new defects (Figure 1, 
subjects C and D). One child showed improvement in VDP (and LCI) between 
baseline and visit two: in this individual the ventilation defects evident at 
baseline were either completely resolved or had reduced in size. 
 
Longitudinal change in lung physiology 
6/14 children had an abnormally elevated LCI (>7.4) at baseline. By visit two, 
LCI values had increased in 11/14, with eight children demonstrating abnormal 
LCI values. At baseline all children had normal spirometry (FEV1 and FEV1/FVC 
z-score >-1.96) and only one child had an FEV1 <-1.64. At visit two all children 
had an FEV1 z score >-1.64 and 13/14 children had an FEV1/FVC z-score >-1.96.  
 
Correlation between imaging and physiology 
At both baseline and visit two there were statistically significant correlations 
between VDP and LCI (r=0.66,p=0.013, r=0.82,p=0.001 respectively) and a 
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significant correlation between LCI and CVmean was observed at visit two (r=0.62, 
p=0.02). There was no significant correlation between FEV1 and FEV1/FVC with    Ǥ ȟ      ȟmean ȋ ? ?Ǥ ? ?ǡ  ? ?Ǥ ? ? ?Ȍ  ȟ ȋ ? ?Ǥ ?ǡ  ? ?Ǥ ? ? ?ȌǤ ȟ	1  ȟ	1/FVC 
demonstrated no significant correlation with other metrics. 
 
 
Discussion 
With the current slow rate of decline in FEV1 in stable CF lung disease, sensitive 
outcome measures of longitudinal change in lung function are needed to guide 
therapy to maintain lung health. Ventilation MRI is capable of detecting 
significant lung function changes in the follow up of children with CF and normal 
spirometry which is not always demonstrable using MBW. Although there was a 
significant group mean increase in LCI values between visits, highlighting the 
potential of LCI as a longitudinal assessment method, LCI was abnormal in only 
two more children at visit two (8/14) compared to baseline (6/14).  Ventilation 
MRI however was abnormal in all children at both time-points, and showed 
increased ventilation heterogeneity over time, quantified by a highly significant 
increase in VDP. The nature of increased ventilation heterogeneity varied 
between subjects, with new unventilated regions present at visit two in some 
patients and others showing an increase in the volume of unventilated regions, 
which were already present at baseline. The sensitivity of ventilation MRI to 
longitudinal therapy response in patients with CF has previously been 
demonstrated (13) but this is the first study to compare ventilation MRI and LCI 
for longitudinal assessment of lung disease progression in children with CF. 
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The observed improved sensitivity of ventilation MRI to longitudinal disease 
progression may be due to its ability to identify changes within lung regions, 
which tend to be small in early disease, whilst LCI is a global assessment of lung 
function measured at a single point.  In addition, unventilated regions of the lung 
will not contribute signal to outcomes relying on gas mixing, causing an 
underestimate of measures such as LCI. 
 
In conclusion, whilst further data is still required, in children with CF and 
clinically stable lung function and normal spirometric values, hyperpolarised gas 
ventilation MRI appears to identify longitudinal changes in early lung disease 
prior to other physiological methods of early lung disease detection.  
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Table 1: Mean (standard deviation) CF patient demographics, lung function and 
ventilation imaging metrics at baseline and visit 2. P-values from Wilcoxon 
signed-ranks test are given for baseline and visit 2 group comparison. 
 Baseline Visit 2 P-value 
Age (years) 10.30 (2.26) 12.07 (2.28) <0.001 
Height (cm) 139.2 (13.89) 148.3 (12.88) <0.001 
Weight (kg) 35.41 (13.26) 40.85 (12.42) <0.001 
FEV1 (z-score) -0.12 (0.80) -0.26 (0.66) 0.349 
FEV1/FVC (z-score) -0.57 (0.65) -0.47 (0.59) 0.903 
RV/TLC (%) 26.80 (4.58) 25.94 (4.38) 0.636 
LCI 7.29 (0.85) 8.09 (1.44) 0.029 
LCIsupine 7.64 (1.03) 8.77 (1.99) 0.042 
Scond 0.048 (0.025) 0.055 (0.029) 0.318 
Sacin 0.132 (0.076) 0.129 (0.076) 0.985 
VDP (%) 4.37 (1.89) 10.8 (4.62) <0.001 
CVmean (%) 15.31 (2.30) 17.94 (3.33) 0.042 
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Figure 1: Representative ventilation MRI slices from four separate CF subjects. 
All four subjects had normal FEV1 at both visits. Subjects A and B demonstrated 
widespread ventilatory defects visible at visit two. VDP increased from 3.1% to 
19.7%, CVmean from 15.9% to 20.1% and LCI from 6.6 to 8.7 for subject A. VDP 
increased from 3.4% to 19.4%, CVmean from 11.9% to 24.5% and LCI from 6.6 to 
9.1 for subject B. Subjects C and D demonstrated localised ventilatory defects 
that largely increased in size from baseline to visit two (as shown by white 
arrows). VDP increased from 4.4% to 9.4%, yet CVmean demonstrated a small 
decline from 15.2% to 14.9%, LCI increased from 6.2 to 6.6 but remains well 
within the normal range for subject C. VDP increased from 7.5% to 10.3%, CVmean 
from 13.3 to 16.6% and LCI from 7.6 to 7.8 for subject D. 
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